Medtronic's struggling spinal division is the sole black mark on an otherwise stellar fiscal 2014 second quarter. But every other division reported gains.
Cardiovascular Systems hopes to raise at least $60 million in a public offering to boost the commercial rollout of its coronary artery device-treatment systems. The cash infusion may also advance international expansion and new clinical trials, according to the Minnesota device company's recent regulatory filing.
A massive study involving next-generation Medtronic devices shows their evolving capacity to do more than just regulate heartbeats; they may also help slow the advance of permanent atrial fibrillation and reduce hospitalization rates, researchers believe.
Solta Medical's master plan to reorganize and revamp continues with the finalization of $40 million in new structured debt financing. The California maker of liposuction, skin resurfacing and other aesthetic medical devices said it plans to use the money to advance its ongoing recovery strategy.
With the success of Erbitux and its patient-steering companion diagnostic fresh in mind, Qiagen and Eli Lilly have struck up their third partnership, reuniting to match genomic knowhow with drug development expertise.
Varian Medical Systems will buy back an additional 6 million shares of common stock through 2014. The company has already been in the midst of an 8-million-share repurchase program that's nearly complete.
California's TriVascular has bagged another $40 million in equity to expand the use of its FDA-approved devices for endovascular aortic repair, used to treat dangerous bulges in blood vessels.
CareFusion is handing over $500 million for GE Healthcare's Vital Signs arm, an acquisition it said will make it a giant in the respiratory and anesthesia consumables business but also fuel a broader global expansion.
Medtronic began a month ago to recall a number of potentially faulty guidewires used for various cardiac procedures, and now the FDA has slapped the effort with its most-serious "Class I" label. At least one patient has been injured, the company said.
Carmat is inching closer to bringing its artificial heart to market, and the French device company is also looking to break into the U.S. through a partnership with one of its major med tech competitors.
Kimberly-Clark is actively exploring a spin-off of its healthcare business, a generator of $1.6 billion in annual net sales and maker of medical devices including catheters, pain pumps and enteral feeding tubes.
Genomic sequencing specialist GenapSys picked up $37 million in Series B financing to help develop and commercialize its diagnostic system for genetic diseases, cancer and microbes.
CardioDx was among the cluster of diagnostics and med tech companies that joined a march to the public markets earlier this fall. But executives have now decided to delay the company's IPO, according to various media reports, citing poor market conditions.
A German appeals court lifted an injunction preventing the sale of Medtronic's transcatheter aortic heart valve in the country, a major defeat for archrival Edwards Lifesciences and the latest development in a nasty patent fight that long ago went international.
California's NeuroPace gained the FDA's long-awaited signoff for its antiepilepsy neurostimulation implant, capping years of development and testing.
Johnson & Johnson will lay off a number of employees as part of a plan to revamp its diabetes arm, driven by ongoing challenges facing the broader industry sector.
It's an incredible story: A YouTube video demonstrating how to free a cork trapped in a wine bottle inspired an Argentine mechanic to develop a simple medical device that uses the same approach to ease difficult births. Becton Dickinson took notice, licensed the tech and plans to manufacture and market a final version around the world.
San Diego's Volcano is facing shareholder pressure to boost its value and find itself a buyer, and analysts believe the intravascular device company could be an ideal target for med tech giants Abbott Laboratories and Medtronic.
Insulin pump maker Tandem Diabetes bagged $120 million in its IPO, pricing shares at the top of its range and feeding optimism that medical device companies can cash in on the boom in biotech debuts.
A Canadian patient is suing Biomet for damages, alleging it sold a malfunctioning and harmful metal-on-metal hip implant. The class-action lawsuit adds to the burden of hundreds of related U.S. court cases already in the pipeline against the Indiana company.